Free Trial

Catalyst Pharmaceuticals (CPRX) Competitors

$15.25
-0.20 (-1.29%)
(As of 09:57 AM ET)

CPRX vs. ANIP, IDYA, PGNX, SYRS, CUE, CERE, ITCI, JAZZ, BPMC, and VKTX

Should you be buying Catalyst Pharmaceuticals stock or one of its competitors? The main competitors of Catalyst Pharmaceuticals include ANI Pharmaceuticals (ANIP), IDEAYA Biosciences (IDYA), Progenics Pharmaceuticals (PGNX), Syros Pharmaceuticals (SYRS), Cue Biopharma (CUE), Cerevel Therapeutics (CERE), Intra-Cellular Therapies (ITCI), Jazz Pharmaceuticals (JAZZ), Blueprint Medicines (BPMC), and Viking Therapeutics (VKTX). These companies are all part of the "medical" sector.

Catalyst Pharmaceuticals vs.

Catalyst Pharmaceuticals (NASDAQ:CPRX) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, community ranking, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.

Catalyst Pharmaceuticals received 60 more outperform votes than ANI Pharmaceuticals when rated by MarketBeat users. Likewise, 74.43% of users gave Catalyst Pharmaceuticals an outperform vote while only 64.64% of users gave ANI Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Catalyst PharmaceuticalsOutperform Votes
486
74.43%
Underperform Votes
167
25.57%
ANI PharmaceuticalsOutperform Votes
426
64.64%
Underperform Votes
233
35.36%

In the previous week, Catalyst Pharmaceuticals had 5 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 16 mentions for Catalyst Pharmaceuticals and 11 mentions for ANI Pharmaceuticals. Catalyst Pharmaceuticals' average media sentiment score of 0.51 beat ANI Pharmaceuticals' score of 0.44 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Catalyst Pharmaceuticals
4 Very Positive mention(s)
5 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
ANI Pharmaceuticals
3 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are owned by institutional investors. 11.0% of Catalyst Pharmaceuticals shares are owned by insiders. Comparatively, 12.7% of ANI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Catalyst Pharmaceuticals has higher earnings, but lower revenue than ANI Pharmaceuticals. Catalyst Pharmaceuticals is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Catalyst Pharmaceuticals$398.20M4.52$71.41M$0.5428.24
ANI Pharmaceuticals$486.82M2.75$18.78M$1.6039.88

Catalyst Pharmaceuticals currently has a consensus target price of $26.71, suggesting a potential upside of 75.18%. ANI Pharmaceuticals has a consensus target price of $81.00, suggesting a potential upside of 26.15%. Given Catalyst Pharmaceuticals' higher probable upside, equities analysts clearly believe Catalyst Pharmaceuticals is more favorable than ANI Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Catalyst Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
ANI Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

Catalyst Pharmaceuticals has a net margin of 15.83% compared to ANI Pharmaceuticals' net margin of 6.87%. Catalyst Pharmaceuticals' return on equity of 25.08% beat ANI Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Catalyst Pharmaceuticals15.83% 25.08% 21.26%
ANI Pharmaceuticals 6.87%17.15%8.29%

Catalyst Pharmaceuticals has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Comparatively, ANI Pharmaceuticals has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500.

Summary

Catalyst Pharmaceuticals beats ANI Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

Get Catalyst Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CPRX vs. The Competition

MetricCatalyst PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.80B$7.30B$5.26B$8.42B
Dividend YieldN/A2.65%2.80%4.06%
P/E Ratio28.2422.12181.7318.38
Price / Sales4.52270.982,298.6676.77
Price / Cash7.6032.7633.9530.83
Price / Book4.625.664.974.32
Net Income$71.41M$147.13M$109.83M$215.80M
7 Day Performance-3.24%-0.72%-0.08%-0.10%
1 Month Performance-5.98%0.44%0.51%0.02%
1 Year Performance30.68%-5.29%1.24%2.98%

Catalyst Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ANIP
ANI Pharmaceuticals
4.7089 of 5 stars
$66.74
-3.0%
$81.00
+21.4%
+29.3%$1.44B$486.82M41.71642Short Interest ↑
High Trading Volume
IDYA
IDEAYA Biosciences
3.1334 of 5 stars
$38.01
-4.1%
$48.27
+27.0%
+56.5%$3.00B$23.39M-18.91124Positive News
Gap Up
PGNX
Progenics Pharmaceuticals
0 of 5 stars
$4.10
flat
N/A+0.0%$355.05M$34.99M-5.3279Gap Up
High Trading Volume
SYRS
Syros Pharmaceuticals
4.3589 of 5 stars
$5.15
-2.8%
$14.00
+171.8%
+53.0%$141.66M$9.94M-1.0368Positive News
CUE
Cue Biopharma
3.7618 of 5 stars
$1.48
-8.6%
$8.00
+440.5%
-60.4%$78.80M$5.49M-1.4053Short Interest ↓
Positive News
Gap Up
CERE
Cerevel Therapeutics
0.09 of 5 stars
$40.02
-0.6%
$42.67
+6.6%
+25.5%$7.34BN/A0.00334
ITCI
Intra-Cellular Therapies
4.7185 of 5 stars
$68.41
-0.2%
$92.73
+35.5%
+5.9%$7.24B$464.37M-58.97610Analyst Forecast
Short Interest ↓
Positive News
JAZZ
Jazz Pharmaceuticals
4.9073 of 5 stars
$112.05
+5.4%
$190.92
+70.4%
-11.6%$6.70B$3.83B23.102,800Positive News
BPMC
Blueprint Medicines
0.6243 of 5 stars
$103.34
-1.0%
$108.00
+4.5%
+84.2%$6.54B$249.38M-21.48655
VKTX
Viking Therapeutics
4.414 of 5 stars
$55.99
+1.8%
$112.38
+100.7%
+121.0%$6.07BN/A-60.2028

Related Companies and Tools

This page (NASDAQ:CPRX) was last updated on 6/13/2024 by MarketBeat.com Staff

From Our Partners